A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)

This study has been completed.
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
First received: February 20, 2009
Last updated: February 26, 2015
Last verified: February 2015